Diagnosis, treatment, and outcomes of encapsulated papillary carcinoma: a single institution experience

Abstract

Background.Encapsulated papillary carcinoma (EPC) is a rare entity of breast cancer accounting for approximately 1–2% of all breast tumours. There are no evidence-based guidelines for the treatment of EPC.Materials and methods.From the database of the National Centre of Pathology (NCP), we obtained pathology reports of 19 patients with histologically confirmed EPC, who were treated at the National Cancer Institute (NCI) in Vilnius, Lithuania, between July 2009 and July 2015. Demographic, diagnostic and treatment data were collected from medical records retrospectively.Results.During the indicated period, 19 patients with EPC were treated at the NCI. Three of them had pure EPC, they were 74 to 81 years of age at the time of diagnosis (mean 76.7 years, median 75 years); all of them are still alive and no disease progression has been observed. Seven patients had EPC associated with carcinoma in situ. Nine patients had EPC associated with invasive breast ductal carcinoma. All patients underwent surgery, in most cases – wide local excision. Only one patient died.Conclusions.EPC is a rare form of breast cancer and usually presents with an invasive breast carcinoma or carcinoma in situ in postmenopausal women. Tumours have an excellent prognosis in the cases of pure EPC and in both EPC associated with carcinoma in situ (CIS) and invasive carcinoma.

Rare Papillary Breast Carcinoma Incidentally Discovered After Trauma-Induced Hematoma

“…Breast carcinoma presenting as a post-traumatic hemorrhagic cyst is rare, but possible [7]. There are only a few reports of EPC presenting after trauma, and much less so specifying a trauma-induced hematoma or hemorrhagic cyst [8,9].…”

<p>Magnetic Resonance Imaging (MRI) Phenotypes May Provide Additional Information for Risk Stratification for Encapsulated Papillary Carcinoma of the Breast</p>

“…Since axillary lymph node metastasis is rare for pure EPCs, the precise axillary staging would not be recommended for every EPC patients and should be determined according to both context-and patient-specific, however, at present has not been clearly established for EPC patients. 20,21 For EPC patients with low-risk stratification indicated above and negative axillary lymph node examination, we suggested follow-up observation. For EPC patients with higher risk stratification indicated above and accompanied by positive axillary lymph nodes, sentinel lymph node biopsy (SLNB) is feasible for axillary staging and further treatment.…”

Papillary carcinoma breast: A tertiary care institute experience

“…Often, papillary carcinomas don't cause any symptoms and are not caught with breast self-examination. [7] In our study all the cases of papillary breast carcinoma presented with clinically palpable breast lump. Papillary carcinoma breast is more frequent in the elderly women (median age of 69.5 years, range (22 to 99) and much more frequent in women than in men.…”